These findings show that CD19-redirected CAR-T cells equipped with humanized scFvs can effectively mediate disease remission in R/R B-ALL patients even in those who have had multiple previous conventional CAR-T cell treatment [29]. Here, CD19 is linked to acute lymphoblastic leukemia.